Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis

F. Suematsu, E. Yukawa, M. Yukawa, M. Minemoto, S. Ohdo, S. Higuchi, Y. Goto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: The steady-state concentrations of digoxin at trough levels were studied to establish the role of patient characteristics in estimating doses for digoxin using routine therapeutic drug monitoring data. Method: The data (n=448) showing steady state after repetitive oral administration in 172 hospitalized neonates and infants were analyzed using Nonlinear Mixed Effect Model (NONMEM), a computer program designed to analyze pharmacokinetics in study populations by allowing pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished using a simple steady-state pharmacokinetic model. The effects of a variety of developmental and demographic factors on the clearance of digoxin were investigated. Results: Estimates generated using NONMEM indicated that clearance of digoxin (1·h-1) was influenced by the demographic variables of age, total body weight, serum creatinine, the coadministration of spironolactone, and the presence or absence of congestive heart failure. The interindividual variability in digoxin clearance was modeled with proportional errors with an estimated coefficient of variation of 32.1%, and the residual variability was 28.9%. In the validation set of 66 patients, the performance (bias, precision) of the final population model was good (mean prediction error -0.04, ng·ml-1; mean absolute prediction error 0.20 ng·ml-1).

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume57
Issue number1
DOIs
Publication statusPublished - Jan 1 2001
Externally publishedYes

Fingerprint

Digoxin
Newborn Infant
Population
Pharmacokinetics
Demography
Spironolactone
Drug Monitoring
Oral Administration
Meta-Analysis
Creatinine
Software
Heart Failure
Body Weight
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. / Suematsu, F.; Yukawa, E.; Yukawa, M.; Minemoto, M.; Ohdo, S.; Higuchi, S.; Goto, Y.

In: European Journal of Clinical Pharmacology, Vol. 57, No. 1, 01.01.2001, p. 19-24.

Research output: Contribution to journalArticle

Suematsu, F. ; Yukawa, E. ; Yukawa, M. ; Minemoto, M. ; Ohdo, S. ; Higuchi, S. ; Goto, Y. / Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. In: European Journal of Clinical Pharmacology. 2001 ; Vol. 57, No. 1. pp. 19-24.
@article{4791e1981bc44b469fffaf4037746419,
title = "Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis",
abstract = "Objective: The steady-state concentrations of digoxin at trough levels were studied to establish the role of patient characteristics in estimating doses for digoxin using routine therapeutic drug monitoring data. Method: The data (n=448) showing steady state after repetitive oral administration in 172 hospitalized neonates and infants were analyzed using Nonlinear Mixed Effect Model (NONMEM), a computer program designed to analyze pharmacokinetics in study populations by allowing pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished using a simple steady-state pharmacokinetic model. The effects of a variety of developmental and demographic factors on the clearance of digoxin were investigated. Results: Estimates generated using NONMEM indicated that clearance of digoxin (1·h-1) was influenced by the demographic variables of age, total body weight, serum creatinine, the coadministration of spironolactone, and the presence or absence of congestive heart failure. The interindividual variability in digoxin clearance was modeled with proportional errors with an estimated coefficient of variation of 32.1{\%}, and the residual variability was 28.9{\%}. In the validation set of 66 patients, the performance (bias, precision) of the final population model was good (mean prediction error -0.04, ng·ml-1; mean absolute prediction error 0.20 ng·ml-1).",
author = "F. Suematsu and E. Yukawa and M. Yukawa and M. Minemoto and S. Ohdo and S. Higuchi and Y. Goto",
year = "2001",
month = "1",
day = "1",
doi = "10.1007/s002280100274",
language = "English",
volume = "57",
pages = "19--24",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis

AU - Suematsu, F.

AU - Yukawa, E.

AU - Yukawa, M.

AU - Minemoto, M.

AU - Ohdo, S.

AU - Higuchi, S.

AU - Goto, Y.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective: The steady-state concentrations of digoxin at trough levels were studied to establish the role of patient characteristics in estimating doses for digoxin using routine therapeutic drug monitoring data. Method: The data (n=448) showing steady state after repetitive oral administration in 172 hospitalized neonates and infants were analyzed using Nonlinear Mixed Effect Model (NONMEM), a computer program designed to analyze pharmacokinetics in study populations by allowing pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished using a simple steady-state pharmacokinetic model. The effects of a variety of developmental and demographic factors on the clearance of digoxin were investigated. Results: Estimates generated using NONMEM indicated that clearance of digoxin (1·h-1) was influenced by the demographic variables of age, total body weight, serum creatinine, the coadministration of spironolactone, and the presence or absence of congestive heart failure. The interindividual variability in digoxin clearance was modeled with proportional errors with an estimated coefficient of variation of 32.1%, and the residual variability was 28.9%. In the validation set of 66 patients, the performance (bias, precision) of the final population model was good (mean prediction error -0.04, ng·ml-1; mean absolute prediction error 0.20 ng·ml-1).

AB - Objective: The steady-state concentrations of digoxin at trough levels were studied to establish the role of patient characteristics in estimating doses for digoxin using routine therapeutic drug monitoring data. Method: The data (n=448) showing steady state after repetitive oral administration in 172 hospitalized neonates and infants were analyzed using Nonlinear Mixed Effect Model (NONMEM), a computer program designed to analyze pharmacokinetics in study populations by allowing pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished using a simple steady-state pharmacokinetic model. The effects of a variety of developmental and demographic factors on the clearance of digoxin were investigated. Results: Estimates generated using NONMEM indicated that clearance of digoxin (1·h-1) was influenced by the demographic variables of age, total body weight, serum creatinine, the coadministration of spironolactone, and the presence or absence of congestive heart failure. The interindividual variability in digoxin clearance was modeled with proportional errors with an estimated coefficient of variation of 32.1%, and the residual variability was 28.9%. In the validation set of 66 patients, the performance (bias, precision) of the final population model was good (mean prediction error -0.04, ng·ml-1; mean absolute prediction error 0.20 ng·ml-1).

UR - http://www.scopus.com/inward/record.url?scp=0035035783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035035783&partnerID=8YFLogxK

U2 - 10.1007/s002280100274

DO - 10.1007/s002280100274

M3 - Article

C2 - 11372585

AN - SCOPUS:0035035783

VL - 57

SP - 19

EP - 24

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -